Biocon Share Price in Focus Surges Nearly 2% After Pertuzumab Biosimilar Gets EU Approval

Biocon has received European Commission approval for Pebrilzo, its biosimilar version of pertuzumab, used in the treatment of HER2-positive breast cancer. The product can now be marketed across the European Union for use in different stages of the disease.
The approval also makes Pebrilzo the first biosimilar to receive authorisation under the European Medicines Agency's new tailored clinical approach. The development follows the product's recent approval in the US.
Treatment Covers Multiple Stages of Breast Cancer
Pebrilzo is a monoclonal antibody supplied as a 420 mg concentrate for infusion. It is approved for use alongside trastuzumab and chemotherapy in certain patients with early-stage, locally advanced and inflammatory HER2-positive breast cancer.
For metastatic or locally recurrent unresectable cases, it can be used with trastuzumab and docetaxel in eligible adult patients who have not previously received anti-HER2 treatment or chemotherapy for metastatic disease.
Clinical Assessment Shows High Similarity
Biocon said its analytical studies and comparative clinical pharmacokinetic data demonstrated high similarity between Pebrilzo and the reference product.
The assessment found no clinically meaningful differences in quality, safety or efficacy.
Fifth Oncology Biosimilar Approved in Europe and the US
With this approval, pertuzumab becomes Biocon's fifth oncology biosimilar to receive approval in both Europe and the United States. The addition further expands its range of cancer treatments.
Biocon CEO and Managing Director Shreehas Tambe said the approval strengthens the company's oncology portfolio and supports its efforts to widen access to high-quality, affordable biologic treatments for patients with HER2-positive breast cancer.
Read More: Sigma Advanced Systems Share Price Hits 5% Upper Circuit After Defence Joint Venture with Spain's EM&E Group!
Biocon Share Price Performance
As of 18 November 2026, at 11:17 AM, Biocon Ltd share price is trading at ₹366.55 per share, reflecting a surge of 1.99% from the previous trading session.
Conclusion
The European approval gives Biocon another approved oncology biosimilar across major markets. Pebrilzo's addition also expands the treatment options available through the company's oncology portfolio.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Nov 18, 2026, 12:09 PM IST

Team Angel One
- Ashoka Buildcon Share Price Surges Over 3%; Emerges as L-1 Bidder for NHAI Project in Gujarat
- Prestige Estates Share Price in Focus; Acquires 50% Stake in Advent Convention
- Jewellery Stocks Including Sky Gold, Kalyan Jewellers and Titan Decline Up to 5.63% as MCX Gold and Silver Prices Fall
- HCLTech Share Price in Focus After Partnering with Cohere for Sovereign AI Solutions
- ACME Solar Share Price in Focus After Signing 150 MW Hybrid Power PPA with NTPC




